Advertisement
Advertisement
February 9, 2022
Perfuze Raises Funds to Support Clinical Study of Millipede Stroke Device
February 9, 2022—Perfuze, an Ireland-based medical device company developing next-generation catheter-based aspiration technology to treat large vessel occlusion acute ischemic stroke, announced it has closed a €22.5 million Series A investment round.
According to Perfuze, proceeds from the financing will be used to support the next stage of the United States clinical study and regulatory clearance of the company’s Millipede system. The funds will also be used to support ongoing development of new products and to initiate commercialization of its technology.
In May 2021, Perfuze announced that the first cohort of patients was successfully treated with the company’s first device, the Millipede 088, which received European CE Mark approval in February 2021.
The company stated that the Series A funding was led by new investors LSP, investing from its LSP Health Economics Fund 2, and Seroba Life Sciences. The round was also supported by new investor SV Health Investors, investing from its Medtech Convergence Fund and existing investors Earlybird, the HBM-MedFocus Fund, Enterprise Ireland, and a syndicate of Irish business veterans and stroke physicians.
Advertisement
Advertisement
